MAPK signaling pathway
Wednesday 11 June 2003
MAPK pathway inhibitors
The MAPK pathway is a key therapeutic target for melanoma as it is activated in most tumors. Despite the clinical success of drugs targeting this pathway, their therapeutic efficacy is limited by the development of drug resistance. To develop effective therapies for melanoma, it is critical to uncover the mechanisms of resistance to BRAF inhibitors and MEK inhibitors. Recent studies on the molecular mechanisms of resistance to inhibitors of the MAPK pathway and potential strategies to overcome resistance will be discussed.
RASs: HRAS, KRAS, NRAS
Kim IA, Fernandes AT, Gupta AK, McKenna WG, Bernhard EJ. The influence of Ras pathway signaling on tumor radiosensitivity. Cancer Metastasis Rev. 2004 Aug;23(3-4):227-36. PMID: 15197325
Hazzalin CA, Mahadevan LC. MAPK-regulated transcription: a continuously variable gene switch? Nat Rev Mol Cell Biol. 2002 Jan;3(1):30-40. PMID: 11823796
Breitkreutz A, Tyers M. MAPK signaling specificity : it takes two to tango. Trends Cell Biol. 2002 Jun ;12(6):254-7. PMID : 12074884